当前位置:首页>产品中心>单抗/多抗>Anti-Human PD-1 Reference Antibody|抗人PD-1参考抗体(靶标:人PD-1)

Anti-Human PD-1 Reference Antibody|抗人PD-1参考抗体(靶标:人PD-1)

  • 货号:RB9THS870366
  • 价格:面议
  • 点击:327

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG4-kappa
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号Q15116
背景信息Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929
• The diverse functions of the PD1 inhibitory pathway., PMID:28990585
• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007
• Overcoming T cell exhaustion in infection and cancer., PMID:25797516
• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727
• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275
• PD-L1., PMID:29097600
别名2639481-06-2
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 432
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 516
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 423
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 277
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 381
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 421
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 361
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 381
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 251
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 298
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 540
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 476
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 568
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 411
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 227
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 449
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 561
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 591
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 495
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 334
总计 33037 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00